NYSEMKT:IGC IGC Pharma (IGC) Stock Price, News & Analysis $0.31 -0.02 (-5.24%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$0.31 0.00 (-0.32%) As of 07/3/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipSEC FilingsBuy This Stock About IGC Pharma Stock (NYSEMKT:IGC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IGC Pharma alerts:Sign Up Key Stats Today's Range$0.32▼$0.3450-Day Range$0.29▼$0.3452-Week Range$0.25▼$0.50Volume214,616 shsAverage Volume341,122 shsMarket Capitalization$24.62 millionP/E RatioN/ADividend YieldN/APrice Target$3.88Consensus RatingBuy Company Overview IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland. Read More IGC Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreIGC MarketRank™: IGC Pharma scored higher than 40% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingIGC Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIGC Pharma has received no research coverage in the past 90 days.Read more about IGC Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for IGC Pharma are expected to decrease in the coming year, from ($0.11) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IGC Pharma is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IGC Pharma is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIGC Pharma has a P/B Ratio of 3.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for IGC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIGC Pharma does not currently pay a dividend.Dividend GrowthIGC Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for IGC. News and Social Media2.3 / 5News Sentiment0.18 News SentimentIGC Pharma has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for IGC Pharma this week, compared to 1 article on an average week.Search Interest5 people have searched for IGC on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, IGC Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders31.48% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.87% of the stock of IGC Pharma is held by institutions.Read more about IGC Pharma's insider trading history. Receive IGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address IGC Stock News HeadlinesIGC Pharma (NYSEMKT:IGC) Stock Price Down 5.2% - What's Next?July 4 at 3:29 AM | americanbankingnews.comEarnings call transcript: IGC Pharma Q2 2025 sees strategic growth in Alzheimer’s research - Investing.comJuly 2 at 7:35 AM | investing.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.July 5 at 2:00 AM | Brownstone Research (Ad)IGC Pharma earnings matched, revenue fell short of estimatesJuly 2 at 7:35 AM | investing.comEarnings call transcript: IGC Pharma Q2 2025 sees strategic growth in Alzheimer’s research - Investing.com UKJuly 2 at 7:35 AM | uk.investing.comIGC Pharma, Inc.: IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's InnovationJune 30, 2025 | finanznachrichten.deIGC Pharma, Inc.: IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025 - FinanzNachrichten.deJune 28, 2025 | finanznachrichten.deIGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025 - MorningstarJune 28, 2025 | morningstar.comMSee More Headlines IGC Stock Analysis - Frequently Asked Questions How have IGC shares performed this year? IGC Pharma's stock was trading at $0.3360 on January 1st, 2025. Since then, IGC shares have decreased by 8.0% and is now trading at $0.3090. How were IGC Pharma's earnings last quarter? IGC Pharma, Inc. (NYSEMKT:IGC) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The firm had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.29 million. IGC Pharma had a negative trailing twelve-month return on equity of 122.44% and a negative net margin of 714.16%. How do I buy shares of IGC Pharma? Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IGC Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that IGC Pharma investors own include Jiuzi (JZXN), Plug Power (PLUG), Avalon GloboCare (ALBT), Ainos (AIMD), Aethlon Medical (AEMD), Aditxt (ADTX) and Adial Pharmaceuticals (ADIL). Company Calendar Last Earnings11/12/2024Today7/05/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEMKT SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSEMKT:IGC CIK1326205 Webigcpharma.com Phone(301) 983-0998Fax240-465-0273Employees61Year FoundedN/APrice Target and Rating Average Stock Price Target$3.88 High Stock Price Target$4.25 Low Stock Price Target$3.50 Potential Upside/Downside+1,154.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13 million Net Margins-714.16% Pretax Margin-712.70% Return on Equity-122.44% Return on Assets-88.40% Debt Debt-to-Equity Ratio0.02 Current Ratio1.15 Quick Ratio0.98 Sales & Book Value Annual Sales$1.27 million Price / Sales19.37 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book3.86Miscellaneous Outstanding Shares79,685,000Free Float54,600,000Market Cap$24.62 million OptionableN/A Beta1.45 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NYSEMKT:IGC) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGC Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGC Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.